Alterations of multiple G protein-mediated signaling pathways are detected in schizophrenia. G proteincoupled receptor kinases (GRKs) and arrestins terminate signaling by G protein-coupled receptors exerting a powerful influence on receptor functions. Modifications of arrestin and/or GRKs expression may contribute to schizophrenia pathology. Cortical expression of arrestins and GRKs was measured postmortem in control and subjects with schizophrenia or schizoaffective disorder. Additionally, arrestin/GRK expression was determined in elderly patients with schizophrenia and age-matched control. Patients with schizophrenia, but not schizoaffective disorder, displayed a reduced concentration of arrestin and GRK mRNAs and GRK3 protein. Arrestins and GRK significantly decreased with age. In elderly patients, GRK6 was reduced, with other GRKs and arrestins unchanged. A reduced cortical concentration of GRKs in schizophrenia (resembling that in aging) may result in altered G protein-dependent signaling, thus contributing to prefrontal deficits in schizophrenia. The data suggest distinct molecular mechanisms underlying schizophrenia and schizoaffective disorder.
Introduction
Schizophrenia is a severe mental illness afflicting about 1% of the population. The dysadaptations of cortical G protein-coupled receptors (GPCRs) in schizophrenia has been the focus of many studies. The up-regulation of D1 receptors in the dorsolateral prefrontal cortex (Abi-Dargham et al., 2002) and abnormalities of D2-like receptors in the cortex in schizophrenia have been reported (Goldsmith et al., 1997; Schmauss, 1996) . Postmortem studies consistently found changes in the cortical serotonin receptors, and many antipsychotic drugs target these receptors (reviewed in Abi-Dargham, 2007) . Complex subtype-and brain region-specific changes in muscarinic receptors have also been reported (Scarr and Dean, 2008) . Thus, the functional state of multiple cortical GPCR subtypes is modified in schizophrenia, although molecular mechanisms or functional consequences of these modifications remain unknown.
Signaling by GPCRs is controlled by multiple desensitization mechanisms. The main desensitization pathway involves activationdependent receptor phosphorylation by G protein-coupled receptor kinases (GRKs) followed by arrestin binding that blocks G proteinmediated signaling (reviewed in Gainetdinov et al., 2004; Gurevich and Gurevich, 2003, 2006) . Two arrestin subtypes, arrestin2 and arrestin3, and four GRK subtypes, GRK2, 3, 5, and 6, are ubiquitously expressed in the brain, each with a distinct distribution pattern (Arriza et al., 1992; Attramadal et al., 1992; Benovic and Gomez, 1993; Bezard et al., 2005; Gurevich et al., 2002 Gurevich et al., , 2004 Premont et al., 1994) . The functional specificity of arrestins and GRK is a matter of controversy. Although arrestin and GRK isoforms interact with many GPCRs in vitro, studies in vivo suggest that receptors are preferentially regulated by specific GRKs (Eckhart et al., 2000; Gainetdinov et al., 1999; Iaccarino et al., 1998a,b; Iwata et al., 2005; Koch et al., 1995; Luo et al., 2008; Naik et al., 2005; Rockman et al., 1996) and arrestins (Bohn et al., 1999 (Bohn et al., , 2000 (Bohn et al., , 2003 Kohout et al., 2001; Oakley et al., 2000) . The signaling via GPCRs depends heavily on the cellular concentration of arrestins and GRKs, which in turn is influenced by the receptor usage (Ahmed et al., 2008a (Ahmed et al., ,b, 2010 Gainetdinov et al., 1999 Gainetdinov et al., , 2003 Gainetdinov et al., , 2004 .
Here we tested the hypothesis that schizophrenia is associated with changes in the expression of arrestin and GRK isoforms in cortical areas implicated in schizophrenia pathology. The dorsolateral prefrontal cortex was the focus of the study, since an impressive body of evidence demonstrates deficits in this region in schizophrenia (reviewed in Lewis and González-Burgos, 2008) . We have investigated the expression of arrestins and GRKs in the prefrontal cortex of patients with schizophrenia in comparison with patients with schizoaffective disorder and normal control, to assess the contribution of mood disturbance in addition to psychosis. Additionally, we have Neurobiology of Disease 44 (2011) 248-258 
